Virbac Offers Exciting Complimentary Livestream Event for Mast Cell Tumour MCT May’
VetClick,
Home > News 2 hours ago 39 views Posted 11th April, 2022 14h01 Author Virbac Animal Health Following the launch of STELFONTA®…
Virbac Identify a Need for More Tumour Diagnostics at London Vet Show
VetClick,
Home > News 27 seconds ago 0 views Posted 10th January, 2022 14h00 Author Virbac Animal Health The busy Virbac ‘STELFONTA®…
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
Intellasia,
16-Dec-2021 Intellasia | PR Newswire Asia | 2:58 AM QBiotics commences the Australian commercial launch of its lead veterinary…
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
Yahoo! Finance USA,
QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, which is approved by the…
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
Yahoo!,
BRISBANE, Australia, Dec. 16, 2021 /PRNewswire/ -- QBiotics Group Limited (QBiotics), a life sciences company developing novel…
AUSTRALIAN LIFE SCIENCE COMPANY, QBIOTICS, LAUNCHES STELFONTA® ITS LEAD VETERINARY PHARMACEUTICAL IN AUSTRALIA, FOLLOWING LAUNCHES IN OTHER KEY GLOBAL MARKETS
AsiaOne,
QBiotics commences the Australian commercial launch of its lead veterinary drug, STELFONTA®, which is approved by the…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
ProfitQuotes.com,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
PharmiWeb,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
News story from Finanz Nachrichten on Wednesday 18 November 2020
Finanz Nachrichten,
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Ticker Tech,
BRISBANE, Australia, Nov. 18, 2020 /PRNewswire/ -- QBiotics Group Limited (QBiotics), a life sciences company developing novel…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Morning Star,
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours PR Newswire BRISBANE, Australia, Nov.
News story from PR Newswire UK on Wednesday 18 November 2020
PR Newswire UK,
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Benzinga,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
WFMZ-TV 69,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
PR Newswire,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
BioTech Gate,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Finanzen.ch,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
AsiaOne,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Yahoo! Finance USA,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics’ STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Intellasia,
17-Nov-2020 Intellasia | PR Newswire Asia | 10:51 AM STELFONTA (tigilanol tiglate injection) is now approved by the U.S.
QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
Finanzen,
STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
BioTech Gate,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Biospace,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
ProfitQuotes.com,
BRISBANE, Australia, April 28, 2020 /PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Jotup,
STELFONTA (tigilanol tiglate) is now available as the first pharmaceutical treatment for all grades of canine non-metastatic…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Spoke,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
News story from Finanz Nachrichten on Tuesday 28 April 2020
Finanz Nachrichten,
QBiotics kommerzialisiert mit Markteinführung von STELFONTA® erstes pharmazeutisches Tigilanol Tiglat-Produkt
Finanzen.ch,
/PRNewswire/ -- Mit der Einführung von STELFONTA® auf dem europäischen Markt hat das australische Life-Science-Unternehmen…
QBiotics commercialise le premier produit pharmaceutique à base de tiglate de tigilanol avec le lancement du STELFONTA®
Le Lézard,
BRISBANE Le STELFONTA® (tiglate de tigilanol), disponible dès aujourd'hui, est le premier traitement pharmaceutique existant…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA
Wall Street Online Denmark,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Ticker Tech,
BRISBANE, Australia, April 28, 2020 /PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has…
News story from Finanz Nachrichten on Tuesday 28 April 2020
Finanz Nachrichten,
QBiotics commercialise le premier produit pharmaceutique à base de tiglate de tigilanol avec le lancement du STELFONTA®
Finanzen.ch,
BRISBANE, Australie, 28 avril 2020 /PRNewswire/ -- QBiotics Group Limited (QBiotics), société australienne de sciences de la vie…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Finanzen.ch,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
WFMZ-TV 69,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Morning Star,
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA® PR Newswire BRISBANE, Australia…
News story from PR Newswire UK on Tuesday 28 April 2020
PR Newswire UK,
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Yahoo! Finance USA,
/PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
Benzinga,
/ / -- Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead…
QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®
AsiaOne,
BRISBANE, Australia, April 28, 2020 /PRNewswire/ -- Australian life sciences company, QBiotics Group Limited (QBiotics) has…
News story from Finanz Nachrichten on Monday 20 January 2020
Finanz Nachrichten,
QBiotics reçoit une première homologation pour le tiglate de tigilanol avec l'autorisation de Stelfonta® par l'Agence européenne du médicament
Le Lézard,
BRISBANE STELFONTA (tiglate de tigilanol) est indiqué dans le traitement de tumeurs mastocytaires sous-cutanées non résécables…
QBiotics reçoit une première homologation pour le tiglate de tigilanol avec l'autorisation de Stelfonta® par l'Agence européenne du médicament
Yahoo! News,
STELFONTA® (tiglate de tigilanol) décroche l'autorisation de l'EMA (l'Agence européenne du médicament), ce qui en fait le…
Erstzulassung für Tigilanol Tiglat von QBiotics: Europäische Arzneimittelagentur EMA erteilt Zulassung für Stelfonta®
PR Newswire,
Die Europäische Arzneimittelagentur EMA erteilt die Zulassung für Tigilanol Tiglat (STELFONTA®), das erste Pharmazeutikum auf…
QBiotics ontvangt eerste registratie voor tigilanol-tiglaat via goedkeuring door het Europees Geneesmiddelenbureau van Stelfonta(R)
PR Newswire,
STELFONTA® (tigilanol-tiglaat) is goedgekeurd door het Europees Geneesmiddelenbureau (EMA), waarmee het de eerste…
QBiotics reçoit une première homologation pour le tiglate de tigilanol avec l'autorisation de Stelfonta® par l'Agence européenne du médicament
PR Newswire,
STELFONTA® (tiglate de tigilanol) décroche l'autorisation de l'EMA (l'Agence européenne du médicament), ce qui en fait le…
QBiotics reçoit une première homologation pour le tiglate de tigilanol avec l'autorisation de Stelfonta® par l'Agence européenne du médicament
Finanzen.ch,
STELFONTA® (tiglate de tigilanol) décroche l'autorisation de l'EMA (l'Agence européenne du médicament), ce qui en fait le…
Erstzulassung für Tigilanol Tiglat von QBiotics: Europäische Arzneimittelagentur EMA erteilt Zulassung für Stelfonta®
Finanzen.ch,
Die Europäische Arzneimittelagentur EMA erteilt die Zulassung für Tigilanol Tiglat (STELFONTA®), das erste Pharmazeutikum auf…
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
Bioportfolio,
STELFONTA (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment…
News story from Finanz Nachrichten on Monday 20 January 2020
Finanz Nachrichten,
News story from PR Newswire UK on Monday 20 January 2020
PR Newswire UK,
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
BioTech Gate,
STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment…
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
PharmiWeb,
STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment…
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of Stelfonta(R)
Finanzen.ch,
STELFONTA® (tigilanol tiglate) approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment…